Treatment of fulminant hepatic failure in rats using a bioartificial liver device containing porcine hepatocytes producing interleukin-1 receptor antagonist

Masahiro Shinoda, Arno W. Tilles, Go Wakabayashi, Atsushi Takayanagi, Hirohisa Harada, Hideaki Obara, Kazuhiro Suganuma, François Berthiaume, Motohide Shimazu, Nobuyoshi Shimizu, Masaki Kitajima, Ronald G. Tompkins, Mehmet Toner, Martin L. Yarmush

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Fulminant hepatic failure (FHF) is a serious clinical condition that is associated with high mortality. There is evidence that FHF is an inflammatory disease, which is supported clinically by elevated serum levels of cytokines. In an effort to develop hepatocytes with additional functions for use in our bioartificial liver (BAL) device, we focused on interleukin-1 (IL-I) blockade as a therapeutic modality. Primary porcine hepatocytes were isolated from the livers of miniature swine and then transfected with an adenoviral vector encoding human interleukin-1 receptor antagonist (AdIL-IRa). The transfected hepatocytes secreted human IL-IRa. These transfected hepatocytes were incorporated into a flat-plate BAL device to evaluate their efficacy in treating D-galactosamine (GaIN)-induced FHF in a rat model. After extracorporeal perfusion with the BAL device containing the transfected hepatocytes, there were significant reductions in the plasma levels of hepatic enzymes (aspartate aminotransferase and alanine aminotransferase) and cytokines (IL-1 and IL-6), indicating a beneficial effect. Animal survival was significantly improved in the treated group compared to the control group. These experiments demonstrate that combining inflammatory cytokine blockade with a functional BAL device may be an effective therapeutic option in the treatment of FHF.

Original languageEnglish
Pages (from-to)1313-1323
Number of pages11
JournalTissue Engineering
Volume12
Issue number5
DOIs
Publication statusPublished - 2006 May

Fingerprint

Artificial Liver
Interleukin-1 Receptors
Acute Liver Failure
Liver
Rats
Hepatocytes
Swine
Equipment and Supplies
Cytokines
Interleukin-1
Galactosamine
Miniature Swine
Aspartate Aminotransferases
Alanine Transaminase
Interleukin-6
Animals
Enzymes
Perfusion
Plasmas
Control Groups

ASJC Scopus subject areas

  • Biophysics
  • Cell Biology
  • Biotechnology

Cite this

Treatment of fulminant hepatic failure in rats using a bioartificial liver device containing porcine hepatocytes producing interleukin-1 receptor antagonist. / Shinoda, Masahiro; Tilles, Arno W.; Wakabayashi, Go; Takayanagi, Atsushi; Harada, Hirohisa; Obara, Hideaki; Suganuma, Kazuhiro; Berthiaume, François; Shimazu, Motohide; Shimizu, Nobuyoshi; Kitajima, Masaki; Tompkins, Ronald G.; Toner, Mehmet; Yarmush, Martin L.

In: Tissue Engineering, Vol. 12, No. 5, 05.2006, p. 1313-1323.

Research output: Contribution to journalArticle

Shinoda, M, Tilles, AW, Wakabayashi, G, Takayanagi, A, Harada, H, Obara, H, Suganuma, K, Berthiaume, F, Shimazu, M, Shimizu, N, Kitajima, M, Tompkins, RG, Toner, M & Yarmush, ML 2006, 'Treatment of fulminant hepatic failure in rats using a bioartificial liver device containing porcine hepatocytes producing interleukin-1 receptor antagonist', Tissue Engineering, vol. 12, no. 5, pp. 1313-1323. https://doi.org/10.1089/ten.2006.12.1313
Shinoda, Masahiro ; Tilles, Arno W. ; Wakabayashi, Go ; Takayanagi, Atsushi ; Harada, Hirohisa ; Obara, Hideaki ; Suganuma, Kazuhiro ; Berthiaume, François ; Shimazu, Motohide ; Shimizu, Nobuyoshi ; Kitajima, Masaki ; Tompkins, Ronald G. ; Toner, Mehmet ; Yarmush, Martin L. / Treatment of fulminant hepatic failure in rats using a bioartificial liver device containing porcine hepatocytes producing interleukin-1 receptor antagonist. In: Tissue Engineering. 2006 ; Vol. 12, No. 5. pp. 1313-1323.
@article{ef59c83c00194244a0c5585bdc4990ef,
title = "Treatment of fulminant hepatic failure in rats using a bioartificial liver device containing porcine hepatocytes producing interleukin-1 receptor antagonist",
abstract = "Fulminant hepatic failure (FHF) is a serious clinical condition that is associated with high mortality. There is evidence that FHF is an inflammatory disease, which is supported clinically by elevated serum levels of cytokines. In an effort to develop hepatocytes with additional functions for use in our bioartificial liver (BAL) device, we focused on interleukin-1 (IL-I) blockade as a therapeutic modality. Primary porcine hepatocytes were isolated from the livers of miniature swine and then transfected with an adenoviral vector encoding human interleukin-1 receptor antagonist (AdIL-IRa). The transfected hepatocytes secreted human IL-IRa. These transfected hepatocytes were incorporated into a flat-plate BAL device to evaluate their efficacy in treating D-galactosamine (GaIN)-induced FHF in a rat model. After extracorporeal perfusion with the BAL device containing the transfected hepatocytes, there were significant reductions in the plasma levels of hepatic enzymes (aspartate aminotransferase and alanine aminotransferase) and cytokines (IL-1 and IL-6), indicating a beneficial effect. Animal survival was significantly improved in the treated group compared to the control group. These experiments demonstrate that combining inflammatory cytokine blockade with a functional BAL device may be an effective therapeutic option in the treatment of FHF.",
author = "Masahiro Shinoda and Tilles, {Arno W.} and Go Wakabayashi and Atsushi Takayanagi and Hirohisa Harada and Hideaki Obara and Kazuhiro Suganuma and Fran{\cc}ois Berthiaume and Motohide Shimazu and Nobuyoshi Shimizu and Masaki Kitajima and Tompkins, {Ronald G.} and Mehmet Toner and Yarmush, {Martin L.}",
year = "2006",
month = "5",
doi = "10.1089/ten.2006.12.1313",
language = "English",
volume = "12",
pages = "1313--1323",
journal = "Tissue Engineering",
issn = "1076-3279",
publisher = "Mary Ann Liebert Inc.",
number = "5",

}

TY - JOUR

T1 - Treatment of fulminant hepatic failure in rats using a bioartificial liver device containing porcine hepatocytes producing interleukin-1 receptor antagonist

AU - Shinoda, Masahiro

AU - Tilles, Arno W.

AU - Wakabayashi, Go

AU - Takayanagi, Atsushi

AU - Harada, Hirohisa

AU - Obara, Hideaki

AU - Suganuma, Kazuhiro

AU - Berthiaume, François

AU - Shimazu, Motohide

AU - Shimizu, Nobuyoshi

AU - Kitajima, Masaki

AU - Tompkins, Ronald G.

AU - Toner, Mehmet

AU - Yarmush, Martin L.

PY - 2006/5

Y1 - 2006/5

N2 - Fulminant hepatic failure (FHF) is a serious clinical condition that is associated with high mortality. There is evidence that FHF is an inflammatory disease, which is supported clinically by elevated serum levels of cytokines. In an effort to develop hepatocytes with additional functions for use in our bioartificial liver (BAL) device, we focused on interleukin-1 (IL-I) blockade as a therapeutic modality. Primary porcine hepatocytes were isolated from the livers of miniature swine and then transfected with an adenoviral vector encoding human interleukin-1 receptor antagonist (AdIL-IRa). The transfected hepatocytes secreted human IL-IRa. These transfected hepatocytes were incorporated into a flat-plate BAL device to evaluate their efficacy in treating D-galactosamine (GaIN)-induced FHF in a rat model. After extracorporeal perfusion with the BAL device containing the transfected hepatocytes, there were significant reductions in the plasma levels of hepatic enzymes (aspartate aminotransferase and alanine aminotransferase) and cytokines (IL-1 and IL-6), indicating a beneficial effect. Animal survival was significantly improved in the treated group compared to the control group. These experiments demonstrate that combining inflammatory cytokine blockade with a functional BAL device may be an effective therapeutic option in the treatment of FHF.

AB - Fulminant hepatic failure (FHF) is a serious clinical condition that is associated with high mortality. There is evidence that FHF is an inflammatory disease, which is supported clinically by elevated serum levels of cytokines. In an effort to develop hepatocytes with additional functions for use in our bioartificial liver (BAL) device, we focused on interleukin-1 (IL-I) blockade as a therapeutic modality. Primary porcine hepatocytes were isolated from the livers of miniature swine and then transfected with an adenoviral vector encoding human interleukin-1 receptor antagonist (AdIL-IRa). The transfected hepatocytes secreted human IL-IRa. These transfected hepatocytes were incorporated into a flat-plate BAL device to evaluate their efficacy in treating D-galactosamine (GaIN)-induced FHF in a rat model. After extracorporeal perfusion with the BAL device containing the transfected hepatocytes, there were significant reductions in the plasma levels of hepatic enzymes (aspartate aminotransferase and alanine aminotransferase) and cytokines (IL-1 and IL-6), indicating a beneficial effect. Animal survival was significantly improved in the treated group compared to the control group. These experiments demonstrate that combining inflammatory cytokine blockade with a functional BAL device may be an effective therapeutic option in the treatment of FHF.

UR - http://www.scopus.com/inward/record.url?scp=33745785901&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33745785901&partnerID=8YFLogxK

U2 - 10.1089/ten.2006.12.1313

DO - 10.1089/ten.2006.12.1313

M3 - Article

C2 - 16771644

AN - SCOPUS:33745785901

VL - 12

SP - 1313

EP - 1323

JO - Tissue Engineering

JF - Tissue Engineering

SN - 1076-3279

IS - 5

ER -